Zika virus has been spreading rapidly across the globe, reaching much further that originally anticipated. 
LRGR has the product to kill the virus at 'sting' point on your body and it appears to have many other uses as well.
"Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997"
otcmarkets.com/stock/lrgr/news
LRGR has the product to kill the virus at 'sting' point on your body and it appears to have many other uses as well."Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997"
otcmarkets.com/stock/lrgr/news
Note
It has been a while coming, but it appears things are finally heating up here. Like to see this one over $1 near term.Note
Looking good here. LRGR sees volume and price appreciation as we head into Zika season in the US."Luminar Media Group, Inc., (Luminar, OTCMKTS:
LRGR) and The Jenex Corporation (Jenex, NEX: $JEN.H) report the completion of a working prototype for the patent pending TherOZap™ device. An Agreement has been signed with the University Health Network to test Therozap™ against the Zika and West Nile viruses. " finance.yahoo.com/news/luminar-media-group-inc-university-132000474.htmlTrade closed: target reached
Happy with these gains. May be worth dip rebuy today/next week.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.